Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Heron Therapeutics Inc Shares Take Wing on Big Insider Buy

On a down day for the Nasdaq, shares of biotech Heron Therapeutics Inc (NASDAQ:HRTX) were faring worse than most in Tuesday trading — until suddenly, they weren’t.

Down 4.8% during ordinary trading hours, shares of Heron suddenly took wing, rising 6.5% in the after-hours market after it was revealed that director and hedge fund manager Kevin Tang had made a series of share purchases of the company over the past few days — totaling 150,000 shares. As can be seen on Insider Monkey’s database, Tang purchased his shares at prices ranging from $19.30 to $23.84, all of which were below the stock’s most recent after-hours price of $24.69.

$managerName
Kevin C. Tang
Tang Capital Management

Our database provides granular details on the trades, clarifying that the great bulk of the purchases, 115,225 shares in all, were made on May 29 at $19.74 per share. Tang proceeded to scoop up a further 2,380 shares at the bargain price of $19.30 on June 1, then topped that off with a final purchase of 32,395 shares at $23.84 yesterday.

What does it mean to you?
It remains to be seen whether Tang will continue his spending spree now that the rest of the stock market is bidding up his targeted shares, or whether he’ll wait to let the share price spike subside before resuming his buying. As for us outside investors, we have a different choice to make.

Do we follow the insider’s lead, on the presumption that he “knows something?” Or do we take our cue rather from Heron’s publicly available financials?

If the latter, then it’s honestly hard to see much attraction in the shares. After last night’s after-hours run-up, Heron Therapeutics Inc is valued at a market cap north of $730 million. Yet the company has no revenues to speak of, is deeply unprofitable ($79.4 million in net losses over the past 12 months), and indeed, hasn’t earned any profits at all since 2006.

While investing in any unprofitable biotech is always an exercise in speculation, this particular “investment” looks even more speculative than most.

 

This $19 trillion industry could destroy the Internet
One bleeding-edge technology is about to put the World Wide Web to bed. And if you act quickly, you could be among the savvy investors who enjoy the profits from this stunning change. Experts are calling it the single largest business opportunity in the history of capitalism… The Economist is calling it “transformative”… But you’ll probably just call it “how I made my millions.” Don’t be too late to the party — click here for one stock to own when the Web goes dark.

Loading...